BioCentury
ARTICLE | Company News

Merrimack cancer news

October 17, 2016 7:00 AM UTC

Merrimack is reducing headcount by 22% to prioritize R&D “on a focused set of systems biology-derived oncology products.” Merrimack said cuts will not affect the commercial team or the commercial laun...